Evaluating Clinical Impact of Linear Energy Transfer Distribution in Proton Therapy for Primary Brain Tumours
Key facts
- Who runs it
- Universitaire Ziekenhuizen KU Leuven
- Where
- Belgium1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 100 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 1 Apr 2029
- Type of study
- Interventional
- Treatments tested
- Radiotherapy
- MRI
- Quality of Life (QoL) assessments.
- Toxicity scoring
- Record updated
- 17 November 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients diagnosed with primary brain tumours including, but not limited to:; Low-grade glioma including: paediatric-type diffuse low-grade glioma, astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted; Ependymal tumours; Tumours of the sellar region including, but not limited to, craniopharyngioma; Medulloblastoma and other embryonal tumours, including, but not limited to, atypical teratoid/rhabdoid tumours; Meningioma; Primary neuroectodermal tumours; Germ cell tumours; Choroid plexus tumours; Pineal tumours
- Both adults and children are eligible for inclusion
- Referred to PARTICLE for proton therapy treatment
- Treatment with PT approved and reimbursed by RIZIV/INAMI
- Ability of patient and/or parents or legal guardian to sign informed consent
Who cannot take part
- Re-irradiation
- Contraindication for MRI (claustrophobia, metallic implants like pacemaker/ICD/neurostimulator)
- Mixed photon-proton planning
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this prospective study is to evaluate whether incorporating linear energy transfer (LET) and variable relative biological effectiveness (RBE) into proton therapy (PT) treatment planning is feasible and may reduce treatment-related adverse events in patients with primary brain tumours. For all participants, the LET distribution and the McNamara variable RBE model will be evaluated during treatment planning. Where feasible, the proton therapy plan will be optimised to reduce areas of high LET in healthy brain tissue while maintaining adequate treatment of the tumour. Participants will undergo standard clinical and MRI follow-up and will additionally be asked to complete quality-of-life questionnaires at several time points.
The group in the trial
- LET-based evaluation in treatment planningTreatment being tested
Treatment: Radiotherapy, MRI, Quality of Life (QoL) assessments., and Toxicity scoring
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluating Clinical Impact of Linear Energy Transfer Distribution in Proton Therapy for Primary Brain Tumours - a Prospective Study
- Record updated
- 17 November 2026